Kamat Amrita, Smith Margaret E, Shelton John M, Richardson James A, Mendelson Carole R
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, USA.
Endocrinology. 2005 May;146(5):2481-8. doi: 10.1210/en.2004-1606. Epub 2005 Jan 27.
The human aromatase (hCYP19) gene is controlled by tissue-specific promoters that lie upstream of tissue-specific first exons. Placenta-specific exon I.1 lies approximately 100,000 bp upstream of exon II. Previously, we observed that genomic sequences within 501 bp upstream of exon I.1 mediate placenta-specific expression. In the present study, transgenic mice were created carrying hCYP19I.1(-246):hGH/hGX, hCYP19I.1(-201):hGH, and hCYP19I.1(-125):hGH fusion genes to further delineate 5'-flanking sequences within 501 bp of exon I.1 that are required to mediate placenta-specific hCYP19 gene expression. As little as 246 bp of hCYP19 exon I.1 5'-flanking sequence was sufficient to direct placenta-specific expression in transgenic mice. By contrast, transgenes containing 201 or 125 bp of exon I.1 5'-flanking DNA were not expressed in mouse placenta. Furthermore, hCYP19I.1(-246):hGX transgene expression was developmentally regulated; expression was observed as early as embryonic d 7.5 (E7.5) in several cells of the trophoblast ectoderm, on E8.5 in some trophoblast giant cells, and by E9.5 in giant cells and the labyrinthine layer. By contrast, expression of the hCYP19I.1(-501):hGH transgene was first observed on E10.5 and was restricted to the labyrinthine layer, which is most analogous to the human syncytiotrophoblast. This suggests the presence of regulatory elements between -501 and -246 bp that may bind inhibitory transcription factors expressed in giant cells. These findings from transgenic experiments together with deletion mapping studies using transfected human placental cells indicate that the concerted interaction of strong placenta-specific enhancers and silencers within this 501-bp region mediate labyrinthine and syncytiotrophoblast-specific CYP19 gene expression.
人类芳香化酶(hCYP19)基因由位于组织特异性首个外显子上游的组织特异性启动子控制。胎盘特异性外显子I.1位于外显子II上游约100,000 bp处。此前,我们观察到外显子I.1上游501 bp内的基因组序列介导胎盘特异性表达。在本研究中,构建了携带hCYP19I.1(-246):hGH/hGX、hCYP19I.1(-201):hGH和hCYP19I.1(-125):hGH融合基因的转基因小鼠,以进一步确定外显子I.1的501 bp内介导胎盘特异性hCYP19基因表达所需的5'侧翼序列。hCYP19外显子I.1的5'侧翼序列仅246 bp就足以在转基因小鼠中指导胎盘特异性表达。相比之下,含有外显子I.1的201或125 bp 5'侧翼DNA的转基因在小鼠胎盘中不表达。此外,hCYP19I.1(-246):hGX转基因表达受发育调控;早在胚胎第7.5天(E7.5),在滋养层外胚层的几个细胞中就观察到表达,在E8.5时在一些滋养层巨细胞中观察到表达,到E9.5时在巨细胞和迷路层中观察到表达。相比之下,hCYP19I.1(-501):hGH转基因的表达最早在E10.5时观察到,且仅限于迷路层,这与人类合体滋养层最为相似。这表明在-501和-246 bp之间存在调控元件,可能与巨细胞中表达的抑制性转录因子结合。这些转基因实验的结果以及使用转染的人胎盘细胞进行的缺失图谱研究表明,该501 bp区域内强大的胎盘特异性增强子和沉默子的协同相互作用介导了迷路层和合体滋养层特异性CYP19基因的表达。